As of June 30, 2026, Kindstar Globalgene Technology, Inc. carries a market capitalization of 926.33M, placing it among publicly traded companies globally. Its enterprise value stands at -553.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 926.33M |
| Enterprise Value | -553.43M |
Kindstar Globalgene Technology, Inc.'s next confirmed earnings release is scheduled for March 26, 2027.
| Earnings Date | 3/26/2027 |
As of June 30, 2026, Kindstar Globalgene Technology, Inc. has 996.05M shares outstanding.
| Shares Outstanding | 996.05M |
These figures are as of June 30, 2026.
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.34 |
As of June 30, 2026, Kindstar Globalgene Technology, Inc. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.84 |
| Quick Ratio | 2.16 |
| Debt / Equity | 14.96 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 3,100.00 |
As of the close on November 17, 2026, Kindstar Globalgene Technology, Inc.'s stock has declined approximately 30.47% over the past 52 weeks. The 50-day moving average sits at 0.91, while the 200-day moving average is 1.03.
| 52-Week Price Change | -30.47% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.03 |
As of June 30, 2026, Kindstar Globalgene Technology, Inc. holds 2.01B in cash and equivalents against 456.50M in total debt, resulting in a net debt position of -292.24M. Total book value stands at 2.98B, with working capital of 1.71B providing operational flexibility.
| Cash & Cash Equivalents | 2.01B |
| Total Debt | 456.50M |
| Net Debt | -292.24M |
| Equity (Book Value) | 2.98B |
| Book Value Per Share | 2.99 |
| Working Capital | 1.71B |
Already premium?